The latter part of 2024 has been an unpredictable and unstable time in many places around the world. It’s the same for the healthcare sector in Asia, including in Japan, where there’s intensifying debate around “off-year” drug repricing, and in South Korea, where a sudden (but quickly reversed) declaration of martial law and subsequent presidential impeachment proceedings have created upheaval.
Despite such instability, major US biopharmaceutical firm Amgen remains committed to steadily expanding its first-in-class product portfolio in Asia and...
